niacinamide has been researched along with Sarcopenia in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Sarcopenia: Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC)." | 7.78 | Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. ( Blanchet, B; Boudou-Rouquette, P; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Pol, S; Ropert, S; Vidal, M, 2012) |
| "Metastatic renal cell cancer (RCC) patients (n = 55) received sorafenib 400 mg b." | 6.75 | Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. ( Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB, 2010) |
| "Patients with advanced hepatocellular carcinoma treated with sorafenib or brivanib in 2008-2011 were included in this retrospective study." | 3.81 | Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. ( Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L, 2015) |
| "Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC)." | 3.78 | Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. ( Blanchet, B; Boudou-Rouquette, P; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Pol, S; Ropert, S; Vidal, M, 2012) |
| "Metastatic renal cell cancer (RCC) patients (n = 55) received sorafenib 400 mg b." | 2.75 | Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. ( Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Song, M | 1 |
| Armenian, SH | 1 |
| Bhandari, R | 1 |
| Lee, K | 1 |
| Ness, K | 1 |
| Putt, M | 1 |
| Lindenfeld, L | 1 |
| Manoukian, S | 1 |
| Wade, K | 1 |
| Dedio, A | 1 |
| Guzman, T | 1 |
| Hampton, I | 1 |
| Lin, K | 1 |
| Baur, J | 1 |
| McCormack, S | 1 |
| Mostoufi-Moab, S | 1 |
| Waltz, TB | 1 |
| Fivenson, EM | 1 |
| Morevati, M | 1 |
| Li, C | 1 |
| Becker, KG | 1 |
| Bohr, VA | 1 |
| Fang, EF | 1 |
| Nault, JC | 1 |
| Pigneur, F | 1 |
| Nelson, AC | 1 |
| Costentin, C | 1 |
| Tselikas, L | 1 |
| Katsahian, S | 1 |
| Diao, G | 1 |
| Laurent, A | 1 |
| Mallat, A | 1 |
| Duvoux, C | 1 |
| Luciani, A | 1 |
| Decaens, T | 1 |
| Antoun, S | 1 |
| Baracos, VE | 1 |
| Birdsell, L | 1 |
| Escudier, B | 1 |
| Sawyer, MB | 1 |
| Mir, O | 1 |
| Coriat, R | 1 |
| Blanchet, B | 1 |
| Durand, JP | 1 |
| Boudou-Rouquette, P | 1 |
| Michels, J | 1 |
| Ropert, S | 1 |
| Vidal, M | 1 |
| Pol, S | 1 |
| Chaussade, S | 1 |
| Goldwasser, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intensive Tailored Exercise Training With NAD+ Precursor Supplementation to Improve Muscle Mass and Fitness in Adolescent and Young Adult Hematopoietic Cell Transplant Survivors[NCT05194397] | Phase 2 | 80 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | ||
| Development of a Prospective Clinico-biological Database in Cachexia in Patients With Colon Cancer[NCT05257135] | 150 participants (Anticipated) | Interventional | 2021-12-23 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Sarcopenia
| Article | Year |
|---|---|
Sarcopenia, Aging and Prospective Interventional Strategies.
Topics: Aging; Animals; Coumarins; Humans; Mitochondria; Molecular Structure; Niacinamide; Sarcopenia; Tomat | 2018 |
2 trials available for niacinamide and Sarcopenia
| Article | Year |
|---|---|
Exercise training and NR supplementation to improve muscle mass and fitness in adolescent and young adult hematopoietic cell transplant survivors: a randomized controlled trial {1}.
Topics: Adolescent; Adult; Dietary Supplements; Exercise; Hematopoietic Stem Cell Transplantation; Humans; M | 2022 |
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Body Mass Index; Carcinoma, Renal Cell; Dose-Respons | 2010 |
2 other studies available for niacinamide and Sarcopenia
| Article | Year |
|---|---|
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Alanine; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; France; Hand-Foot Syndrome; Hu | 2015 |
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Rela | 2012 |